bioAffinity Technologies, Inc.BIAF
Price (close)
$7.93
Market cap
—
P/E
—
Revenue (TTM)
$5.9M
Net income
-$15.2M
Dividend yield
—
1-year total return
-84.5%
Net margin
-257.3%
Revenue growth
-23.2%
Debt / equity
0.01x
What bioAffinity Technologies, Inc. does.
develop noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry
and automated analysis informed by machine learning, a form of artificial intelligence (AI). Our first commercial diagnostic test,
Lung addresses the need for noninvasive detection of early-stage lung cancer with the proven ability to detect the leading cancer
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $6.9M | $7.9M | $9.4M | $6.2M |
| Net income | — | -$6.3M | -$8.2M | -$7.9M | -$9.0M | -$14.9M |
| Free cash flow | — | — | -$4.3M | -$6.1M | -$7.3M | -$9.4M |
More on BIAF.
- bioAffinity Technologies, Inc. summary
- bioAffinity Technologies, Inc. financial statements
- bioAffinity Technologies, Inc. key metrics
- bioAffinity Technologies, Inc. health scores and style box
- bioAffinity Technologies, Inc. earnings
- bioAffinity Technologies, Inc. dividends
- bioAffinity Technologies, Inc. valuation
- bioAffinity Technologies, Inc. ownership and insiders
- bioAffinity Technologies, Inc. peers
Figures from bioAffinity Technologies, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.